New targeted radiation treatment reduces bone pain, extends survival in prostate cancer patients

Prostate cancer that has spread to the bones can cause pain and fractures.

Loyola University Medical Center is among the first hospitals in Chicago to offer a new targeted that can reduce bone pain and the incidence of fractures – and also extend patients' lives.

The treatment, recently approved by the Food and Drug Administration, is called Xofigo®. A , radium-223, is injected into the patient. Because it is similar to calcium, radium-223 binds to the bone. Radium-223 delivers high- over a short distance, providing a targeted treatment that is less damaging to other structures or tissues, said Robert Wagner, MD, medical director of Nuclear Medicine in Loyola's Department of Radiology.

Radium-223 is rapidly cleared from the blood stream. Fifteen minutes after injection, about 20 percent of the injected radioactivity remains in the blood. By 24 hours, less than 1 percent of radioactivity remains.

Xofigo is indicated for prostate cancer patients in which:

- the cancer has spread to the bones, but not to other organs

- the cancer is not responding to hormone therapy or surgery that blocks production of testosterone, and

- the cancer spread to the bones is causing other serious symptoms.

Radium-223 is injected into an IV line in a patient's vein, in a procedure that takes less than 5 minutes. The patient receives a series of six injections, given once every four to six weeks.

Side effects can include upset stomach, diarrhea, swelling in the hands and feet and decreased counts of , and platelets.

"While the treatment is not a cure, it can enable patients to live longer, with significantly improved quality of life," Wagner said.

add to favorites email to friend print save as pdf

Related Stories

First Phase III trial of an alpha-pharmaceutical

Sep 23, 2011

Until recently, options for patients with bone metastases from advanced prostate cancer have been very limited. But now the first Phase III study of an alpha-pharmaceutical in these patients has shown that it can prolong ...

New therapy extends life for prostate cancer patients

Jun 11, 2012

Prostate cancer patients with advanced tumors that have spread to bone have a poor chance of surviving. Patients with the disease may now live longer with a new line of radioisotope therapy, say researchers at the Society ...

Recommended for you

Immune checkpoint inhibitors may work in brain cancers

17 hours ago

New evidence that immune checkpoint inhibitors may work in glioblastoma and brain metastases was presented today by Dr Anna Sophie Berghoff at the ESMO Symposium on Immuno-Oncology 2014 in Geneva, Switzerland.

New model of follow up for breast cancer patients

20 hours ago

Public health researchers from the University of Adelaide have evaluated international breast cancer guidelines, finding that there is potential to improve surveillance of breast cancer survivors from both a patient and health ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.